seekingalpha.com
/1 month ago
Latest updates for Celg.rt
Fresh curated links around CELG.RT are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficac
- Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases
- Carclo plc (CCEGF) Q4 2026 Earnings Call Transcript
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
seekingalpha.com
/1 month ago
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases...
investing.com
/20 hours ago
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
seekingalpha.com
/1 month ago
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com
/1 month ago
Celsius Holdings, Inc. (CELH) Presents at 23rd annual dbAccess Global Consumer Conference Transcript
seekingalpha.com
/1 month ago
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare H...
seekingalpha.com
/1 month ago
Millicom Cellular: A Rare Telecom Growth Story With A 3% Yield
finance.yahoo.com
/1 month ago
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
biopharmadive.com
/17 hours ago
Celcuity gains FDA approval for closely-watched breast cancer drug
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.
cantechletter.com
/1 month ago
Should you sell your GigaCloud Technology stock?
Roth analyst Matt Koranda maintained a “Neutral” rating and $40.00 target on GigaCloud Technology (GigaCloud Technology Stock Quote, Chart, News, Analysts, Financials NASDAQ:GCT) i...
seekingalpha.com
/1 month ago
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
fool.com
/1 month ago
Radcom (RDCM) Q1 2026 Earnings Transcript
Image source: The Motley Fool. DATEMay 19, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Benny EppsteinChief Financial Officer — Hod CohenNeed a quote from a Motley...
fool.com
/1 month ago
Radcom (RDCM) Q1 2026 Earnings Transcript
Image source: The Motley Fool. DATEMay 19, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Benny EppsteinChief Financial Officer — Hod CohenNeed a quote from a Motley...
seekingalpha.com
/1 month ago
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare H...
fool.com
/1 month ago
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Celg.rt
seekingalpha.com
Recent coverage from public sources
Public source
finance.yahoo.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
biopharmadive.com
Recent coverage from public sources
Public source
cantechletter.com
Recent coverage from public sources
Public source